Literature DB >> 15891270

Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.

Joseph Prandota1.   

Abstract

Analysis of literature data on drug-induced hepatotoxicity reveals that often upper respiratory febrile illnesses and/or inflammation states precede liver injury/diseases related to administration of drugs or hepatotoxicity associated with administration of therapeutic doses of acetaminophen in some genetically predisposed subjects. The goals of this paper are to review the potential role of alterations in the balance between TH1 cells producing cytokines associated with a cell-mediated response and TH2 cells associated with an antibody response, as well as other endogenous substances, eg, growth factors, leading to a shift in immune response to one that may participate in the liver cells injury during administration of certain drugs, especially in subjects with genetic polymorphisms in drug-metabolizing enzymes. The papers cited in this review were selected to illustrate specific issue related to how profuse and dysregulated production of cytokines, growth factors, and/or other endogenous substances during viral/bacterial infections and inflammation states play a role in the development of drug-induced liver injury. Several cases of liver injury related to administration of drugs appear to be initiated or intensified by upper respiratory febrile illnesses and/or inflammation states, which stimulate sometimes dysregulated production of interferon gamma and/or other proinflammatory cytokines/growth factors. This, in turn, results in down-regulation of various induced and constitutive isoforms of cytochromes P-450, and other enzymes involved in the metabolism of several exogenous (eg, drugs) and endogenous lipophilic (eg, steroids) substances, thus having an important impact on the alterations in bioactivation and detoxication processes in the body and on the balance between production, utilization, and elimination of endogenous bioproducts of these reactions. Activation of systemic host defense mechanisms results in down-regulation of various enzymes involved in drug metabolism and elimination, as well as in production, utilization, and excretion of many endogenous substances that have beneficial effects on vital processes in the body. It seems that treatment of acute and chronic infections and/or inflammations with, for example, antibacterials not metabolized in the liver, and use of medications that decrease proinflammatory cytokine levels (eg, pentoxifylline, a TNF-alpha synthesis inhibitor, directed against TNF-alpha-induced priming of human neutrophils, immunotherapy with IL-4, IL-1 receptor antagonists or factors inducing IL-1ra, dietary supplementation with long-chain n-3 fatty acids, and other antioxidant agents) may perhaps, in some cases, be helpful in the prevention and management of drug-induced hepatotoxicity. Drug-mediated injuries may eventually be prevented by screening methods that can identify genetic polymorphism of drug-metabolizing enzymes and gene polymorphisms or RNA-expression profiles of some proinflammatory cytokines before a patient uses a drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15891270

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  15 in total

1.  DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes.

Authors:  Mao Zhao; Luan Xiaofei; Cao Gang; Liu Wei; Xiong Jing; Hu Gang; Chen Ruini; Ning Rui; Shang Wei; Yang Jian; Yan Bingfang
Journal:  Biochem Pharmacol       Date:  2012-06-21       Impact factor: 5.858

Review 2.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 3.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 4.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 5.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

6.  Concurrent Inflammation Augments Antimalarial Drugs-Induced Liver Injury in Rats.

Authors:  Hossein Niknahad; Reza Heidari; Roya Firuzi; Farzaneh Abazari; Maral Ramezani; Negar Azarpira; Massood Hosseinzadeh; Asma Najibi; Arastoo Saeedi
Journal:  Adv Pharm Bull       Date:  2016-12-22

7.  Zinc-gene interaction related to inflammatory/immune response in ageing.

Authors:  Eugenio Mocchegiani; Marco Malavolta
Journal:  Genes Nutr       Date:  2008-07       Impact factor: 5.523

8.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

Review 9.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

Review 10.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.